text: <unk>  is a kinase inhibitor that is FDA approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) that has progressed on or is intolerant to crizotinib.   Common adverse reactions include nausea, diarrhea, fatigue, cough, and headache.
option_0: Brigatinib
option_1: Fostamatinib
option_2: Neratinib
option_3: Lenvatinib
option_4: Dasatinib
option_5: Lorlatinib
option_6: Enasidenib
option_7: Afatinib